{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Gastroesophageal+Junction+Adenocarcinoma&page=2", "query": { "condition": "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Gastroesophageal+Junction+Adenocarcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-21T15:09:05.745Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06628310", "title": "A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Telisotuzumab Adizutecan", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2024-12-13", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-07-21T15:09:05.745Z", "location_count": 8, "location_summary": "Duarte, California • Irvine, California • Santa Monica, California + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06628310" }, { "nct_id": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Renal Cell Carcinoma", "Non-Small Cell Lung Cancer", "Castration-resistant Prostate Cancer", "Triple Negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Hepatocellular Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Colorectal Cancer", "Head and Neck Cancer", "Differentiated Thyroid Cancer", "Lower Esophageal Cancer" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" }, { "name": "atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 914, "start_date": "2017-09-05", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-07-21T15:09:05.745Z", "location_count": 57, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03170960" }, { "nct_id": "NCT00757172", "title": "Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Esophageal Cancer" ], "interventions": [ { "name": "panitumumab", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2009-01", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-03-11", "last_synced_at": "2026-07-21T15:09:05.745Z", "location_count": 21, "location_summary": "Savannah, Georgia • Chicago, Illinois • Evanston, Illinois + 15 more", "locations": [ { "city": "Savannah", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00757172" }, { "nct_id": "NCT04522336", "title": "Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Localized Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-09-16", "completion_date": "2027-07-18", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-07-21T15:09:05.745Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04522336" }, { "nct_id": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1756, "start_date": "2013-01-31", "completion_date": "2019-12-16", "has_results": true, "last_update_posted_date": "2021-12-20", "last_synced_at": "2026-07-21T15:09:05.745Z", "location_count": 53, "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 45 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01772004" }, { "nct_id": "NCT04391049", "title": "Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Esophageal Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Squamous Cell Carcinoma", "Squamous Cell Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Telomerase-specific Type 5 Adenovirus OBP-301", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-12-02", "completion_date": "2026-10-01", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-07-21T15:09:05.745Z", "location_count": 17, "location_summary": "Duarte, California • South Pasadena, California • Upland, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04391049" }, { "nct_id": "NCT05207722", "title": "CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic HER2 Positive Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "CYNK-101", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Recombinant Human Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celularity Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2022-04-14", "completion_date": "2024-02-15", "has_results": false, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-07-21T15:09:05.745Z", "location_count": 3, "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05207722" }, { "nct_id": "NCT00069953", "title": "Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 43, "start_date": "2003-09", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2017-02-17", "last_synced_at": "2026-07-21T15:09:05.745Z", "location_count": 97, "location_summary": "Burbank, California • Hayward, California • Mission Hills, California + 72 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00069953" }, { "nct_id": "NCT07069712", "title": "A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Adenocarcinoma" ], "interventions": [ { "name": "AZD0901", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan (T-DXd)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "FLOT Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-07-17", "completion_date": "2028-09-06", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-07-21T15:09:05.745Z", "location_count": 7, "location_summary": "Newark, Delaware • Washington D.C., District of Columbia • Fairway, Kansas + 3 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "North Shores", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07069712" }, { "nct_id": "NCT05067842", "title": "Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma Esophagus" ], "interventions": [ { "name": "Circulating tumor DNA(ctDNA) level measurement", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2022-05-13", "completion_date": "2025-05-30", "has_results": false, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-07-21T15:09:05.745Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05067842" } ] }